Skip to main content

5 Must-Read Analyst Questions From Nordson’s Q1 Earnings Call

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

NDSN Cover Image

Nordson’s first quarter performance was well received by the market, driven by broad-based revenue growth across all segments and sustained margin expansion. Management attributed the results to solid execution in key end markets such as electronics, medical, and industrial applications, with a notable increase in order entry and backlog supporting these gains. CEO Sundaram Nagarajan highlighted the company’s ability to leverage its differentiated technology and close-to-customer approach, stating, “All 3 segments contributed to our organic growth performance, surpassing the midpoint expectations of last quarter’s sales and earnings guidance.”

Is now the time to buy NDSN? Find out in our full research report (it’s free for active Edge members).

Nordson (NDSN) Q1 CY2026 Highlights:

  • Revenue: $740.8 million vs analyst estimates of $727.8 million (8.5% year-on-year growth, 1.8% beat)
  • Adjusted EPS: $2.86 vs analyst estimates of $2.82 (1.5% beat)
  • Adjusted EBITDA: $235.2 million vs analyst estimates of $236.8 million (31.7% margin, 0.7% miss)
  • The company lifted its revenue guidance for the full year to $2.97 billion at the midpoint from $2.92 billion, a 1.7% increase
  • Management raised its full-year Adjusted EPS guidance to $11.55 at the midpoint, a 2.2% increase
  • Operating Margin: 26.6%, up from 24.7% in the same quarter last year
  • Organic Revenue rose 6.6% year on year (miss)
  • Market Capitalization: $16.04 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Nordson’s Q1 Earnings Call

  • Matt Summerville (D.A. Davidson): Asked whether medical growth is now sustainably on track and for more color on the near-term margin headwind. CFO Daniel Hopgood confirmed medical is returning to normalized growth, with the headwind tied to a regulatory material change expected to resolve later this year.

  • Matt Summerville (D.A. Davidson): Inquired about Nordson’s positioning in the semiconductor cycle and the durability of current order momentum. CEO Sundaram Nagarajan described the cycle as early stage, citing customer diversification and new technology co-development as key strengths.

  • Jeffrey Hammond (KeyBanc Capital Markets): Questioned margin trends in Industrial Precision Solutions and the impact of inflationary costs. Hopgood and Nagarajan addressed inflation and tariffs as headwinds, noting selective pricing and cost actions to preserve margins.

  • Michael Halloran (Baird): Sought clarity on guidance assumptions, backlog conversion timing, and macro risks. Hopgood explained that most backlog converts within six months, with guidance prudently assuming current demand trends but factoring in potential macro volatility.

  • Andrew Buscaglia (BNP Paribas): Asked about the mix of systems versus aftermarket parts in Industrial Precision and the outlook for M&A. Management reported improved order entry in both systems and consumables, and noted a robust but disciplined M&A pipeline focused on medical and bolt-on technology deals.

Catalysts in Upcoming Quarters

In future quarters, the StockStory team will be monitoring (1) sustained order entry and backlog trends across electronics and medical segments, (2) the integration and commercial impact of the CapstanAG acquisition in precision agriculture, and (3) the company’s ability to offset inflationary and tariff headwinds through pricing and operational efficiencies. Execution on new product introductions and continued cash flow strength will also be key signposts for assessing ongoing momentum.

Nordson currently trades at $287.87, up from $276.20 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  265.29
+0.00 (0.00%)
AAPL  308.33
+0.00 (0.00%)
AMD  503.89
+0.00 (0.00%)
BAC  52.20
+0.00 (0.00%)
GOOG  384.84
+0.00 (0.00%)
META  612.34
+0.00 (0.00%)
MSFT  416.03
+0.00 (0.00%)
NVDA  214.86
+0.00 (0.00%)
ORCL  193.06
+0.00 (0.00%)
TSLA  433.59
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.